Basel, April 25, 2014 - Novartis announced today top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease (COPD), which met its primary objective. Once-daily Onbrez® Breezhaler® (indacaterol) 150 mcg demonstrated non-inferiority in lung function at week 12 to twice-daily Seretide®* (salmeterol/fluticasone propionate (SFC)) 50/500 mcg in patients with moderate COPD and no exacerbations in the previous year.
Basel, April 24, 2014 - Commenting on the results, Joseph Jimenez, CEO of Novartis, said:"Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including EU and US approval of Xolair in chronic spontaneous urticaria and significant milestones for Bexsero. The transformational deals announced on Tuesday position the company for future success based on our sharpened focus, innovation power and financial strength."
Basel, April 23, 2014 - Novartis, in partnership with world-renowned photographer Anne Geddes, the Confederation of Meningitis Organisations (CoMO) and charities around the world, has announced the publication of an eBook featuring inspirational images of meningococcal disease survivors from across the globe who have participated in the Protecting Our Tomorrows: Portraits of Meningococcal Disease campaign.
Basel, April 23, 2014 - New analyses of pooled data from the FREEDOMS and FREEDOMS II trials will be presented at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pennsylvania, and will show the consistent efficacy of Gilenya® (fingolimod) on four key measures of multiple sclerosis (MS) disease activity - reducing relapses, new MRI lesion counts, brain volume loss and disability progression.
Basel, April 22, 2014 - Novartis announced today that it has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them.
Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014. Mr. George succeeds Kevin Buehler who is retiring from the company after a distinguished 30-year career at Alcon, the global leader in eye care.
Basel, Switzerland, April 7, 2014 - Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign.
Basel, April 7, 2014 - Novartis announced today that Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a Breakthrough Therapy designation from the United States Food and Drug Administration (FDA).